Arcturus Therapeutics Holdings Inc. (ARCT) News

Arcturus Therapeutics Holdings Inc. (ARCT): $20.11

-0.33 (-1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ARCT News Items

ARCT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ARCT News Highlights

  • ARCT's 30 day story count now stands at 7.
  • Over the past 24 days, the trend for ARCT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ARCT are ALIM and BEAT.

Latest ARCT News From Around the Web

Below are the latest news stories about Arcturus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ARCT as an investment opportunity.

Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -55.26% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, February 19, 2022--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Yahoo | February 19, 2022

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

SAN DIEGO, February 16, 2022--Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

Yahoo | February 16, 2022

Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Business Wire | February 8, 2022

How Much Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Do Insiders Own?

A look at the shareholders of Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) can tell us which group is most...

Yahoo | January 31, 2022

Arcturus says messenger RNA vaccines raised antibody levels as boosters against Omicron

Citing data from its Phase 1/2 booster study for ARCT-154 and ARCT-165, Arcturus Therapeutics (ARCT) says that the companys self-amplifying mRNA vaccine candidates strongly

Seeking Alpha | January 25, 2022

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

SAN DIEGO, January 25, 2022--Arcturus Reports Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Trial

Yahoo | January 25, 2022

Arcturus Therapeutics falls 9% amid announcement of COVID-19 booster study data

Arcturus Therapeutics <> said data from ARCT-154 and ARCT-165 booster trial showed neutralizing antibody responses to SARS-CoV-2 and several variants.Full cohort data from

Seeking Alpha | January 24, 2022

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern. Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) Comirnaty immunization, demonstrated robust antibody responses

Yahoo | January 24, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5837 seconds.